Advertisement

Critical role of IL-17 in experimental arthritis

  • Marije I. Koenders
  • Wim B. van den Berg
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Since the discovery of IL-17 expression in synovial fluid and biopsies in rheumatoid arthritis patients, the role of this pro-inflammatory T cell cytokine in arthritis has been extensively studied using animal models of arthritis. In this chapter, an overview is given of the most important publications elucidating the role of IL-17 in the onset and the progression of experimental arthritis. IL-17 is essential for normal T and B cell development, but is also locally involved in the arthritic process, enhancing the expression of pro-inflammatory cytokines and chemokines. IL-17 also contributes to joint destruction directly by up-regulation of matrix metalloproteinases and stimulating osteoclastogenesis through RANKL induction. The recently discovered Th17 cell is regarded as the main source of IL-17, and the influence of IL-12/IL-23 and other mediators in experimental arthritis is discussed.

Keywords

Experimental Autoimmune Encephalomyelitis Bone Erosion Joint Inflammation Cartilage Destruction Experimental Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR, Schwarzenberger P, van den Berg WB, Lubberts E (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metal-loproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 52: 3239–3247PubMedCrossRefGoogle Scholar
  2. 2.
    Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171: 6173–6177PubMedGoogle Scholar
  3. 3.
    Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y (2003) IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 100: 5986–5990PubMedCrossRefGoogle Scholar
  4. 4.
    Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB (2001) IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167: 1004–1013PubMedGoogle Scholar
  5. 5.
    Bush KA, Farmer KM, Walker JS, Kirkham BW (2002) Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 46: 802–805PubMedCrossRefGoogle Scholar
  6. 6.
    Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A (2000) Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis 59: 529–532PubMedCrossRefGoogle Scholar
  7. 7.
    Koenders MI, Lubberts E, van de Loo FA, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Kolls JK, Di Padova FE, Joosten LA, van den Berg WB (2006) Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 176: 6262–6269PubMedGoogle Scholar
  8. 8.
    Van Bezooijen RL, van der Wee-Pals L, Papapoulos SE, Löwik CW (2002) Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 61: 870–876PubMedCrossRefGoogle Scholar
  9. 9.
    Chabaud M, Miossec P (2001) The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 44: 1293–1303PubMedCrossRefGoogle Scholar
  10. 10.
    Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Kolls JK, Joosten LA, van den Berg WB (2005) Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1. Arthritis Rheum 52: 975–983PubMedCrossRefGoogle Scholar
  11. 11.
    Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 170: 2655–2662PubMedGoogle Scholar
  12. 12.
    Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50: 650–659PubMedCrossRefGoogle Scholar
  13. 13.
    Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR, Schwarzenberger P, van den Berg WB, Lubberts E (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metal loproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 52:3239–3247PubMedCrossRefGoogle Scholar
  14. 14.
    Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, Boots AM, Gram H, Joosten LA, van den Berg WB (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167: 141–149PubMedGoogle Scholar
  15. 15.
    Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910–1914PubMedCrossRefGoogle Scholar
  16. 16.
    Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ (2003) Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198: 1951–1957PubMedCrossRefGoogle Scholar
  17. 17.
    Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, Jin HT, Min SY, Ju JH, Park KS et al (2006) STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176: 5652–5661PubMedGoogle Scholar
  18. 18.
    Guedez YB, Whittington KB, Clayton JL, Joosten LA, van de Loo FA, van den Berg WB, Rosloniec EF (2001) Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 44: 2413–2424PubMedCrossRefGoogle Scholar
  19. 19.
    Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB (2007) Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 56: 1145–1151PubMedCrossRefGoogle Scholar
  20. 20.
    Irmler IM, Gajda M, Bräuer R (2007) Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 179: 6228–6236PubMedGoogle Scholar
  21. 21.
    Glant TT, Finnegan A, Mikecz K (2003) Proteoglycan-induced arthritis: Immune regulation, cellular mechanisms, and genetics. Crit Rev Immunol 23: 199–250PubMedCrossRefGoogle Scholar
  22. 22.
    Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB (2000) IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 105: 1697–1710PubMedCrossRefGoogle Scholar
  23. 23.
    Sarkar S, Tesmer LA, Hindnavis V, Endres JL, Fox DA (2007) Interleukin-17 as a molecular target in immune-mediated arthritis: Immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum 56: 89–100PubMedCrossRefGoogle Scholar
  24. 24.
    Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N, Sakaguchi S (2007) T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 204: 41–47PubMedCrossRefGoogle Scholar
  25. 25.
    Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen loproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 52:3239–3247Google Scholar
  26. 26.
    Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY (1998) Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology. J Immunol 160: 5654–5660PubMedGoogle Scholar
  27. 27.
    Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, Zheng XX, Hancock WW, Maslinski W, Li XC, Strom TB, Moll T (2004) Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 173: 5818–5826PubMedGoogle Scholar
  28. 28.
    Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, Yoshikai Y (2007) IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol 37: 2744–2752PubMedCrossRefGoogle Scholar
  29. 29.
    Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith JC Jr, Collins M (2007) Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56: 1152–1163PubMedCrossRefGoogle Scholar
  30. 30.
    Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, Nickerson-Nutter C, Fouser LA, Young DA (2008) IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118: 597–607PubMedGoogle Scholar
  31. 31.
    Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, Heppner FL, Renauld JC, Becher B (2007) IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 179: 8098–8104PubMedGoogle Scholar
  32. 32.
    Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N (2004) Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol 173: 1171–1178PubMedGoogle Scholar
  33. 33.
    Cao Y, Doodes PD, Glant TT, Finnegan A (2008) IL-27 Induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol 180: 922–930PubMedGoogle Scholar
  34. 34.
    Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB (2008) Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 118: 205–216PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2009

Authors and Affiliations

  • Marije I. Koenders
    • 1
  • Wim B. van den Berg
    • 1
  1. 1.Rheumatology Research and Advanced TherapeuticsRadboud University Nijmegen Medical CenterNijmegenThe Netherlands

Personalised recommendations